CY1106249T1 - Συνθεση υπο τη μορφη πηκτωματος προβλεπομενη ωστε να δεχεται ενα δραστικο παραγοντα σε διαλυση ή εναιωρηση ειδικα για εφαρμογη επι ενος βλεννογονου και μεθοδος παρασκευης - Google Patents

Συνθεση υπο τη μορφη πηκτωματος προβλεπομενη ωστε να δεχεται ενα δραστικο παραγοντα σε διαλυση ή εναιωρηση ειδικα για εφαρμογη επι ενος βλεννογονου και μεθοδος παρασκευης

Info

Publication number
CY1106249T1
CY1106249T1 CY20061101679T CY061101679T CY1106249T1 CY 1106249 T1 CY1106249 T1 CY 1106249T1 CY 20061101679 T CY20061101679 T CY 20061101679T CY 061101679 T CY061101679 T CY 061101679T CY 1106249 T1 CY1106249 T1 CY 1106249T1
Authority
CY
Cyprus
Prior art keywords
active agent
composition
mucosa
preparation
receive
Prior art date
Application number
CY20061101679T
Other languages
Greek (el)
English (en)
Inventor
Jack Auzerie
Original Assignee
Ellipse Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellipse Pharmaceuticals filed Critical Ellipse Pharmaceuticals
Publication of CY1106249T1 publication Critical patent/CY1106249T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Detergent Compositions (AREA)
CY20061101679T 1999-12-14 2006-11-16 Συνθεση υπο τη μορφη πηκτωματος προβλεπομενη ωστε να δεχεται ενα δραστικο παραγοντα σε διαλυση ή εναιωρηση ειδικα για εφαρμογη επι ενος βλεννογονου και μεθοδος παρασκευης CY1106249T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9915763A FR2802097B1 (fr) 1999-12-14 1999-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
PCT/FR2000/003533 WO2001043720A1 (fr) 1999-12-14 2000-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication

Publications (1)

Publication Number Publication Date
CY1106249T1 true CY1106249T1 (el) 2011-06-08

Family

ID=9553244

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101679T CY1106249T1 (el) 1999-12-14 2006-11-16 Συνθεση υπο τη μορφη πηκτωματος προβλεπομενη ωστε να δεχεται ενα δραστικο παραγοντα σε διαλυση ή εναιωρηση ειδικα για εφαρμογη επι ενος βλεννογονου και μεθοδος παρασκευης

Country Status (13)

Country Link
US (1) US20030091642A1 (enExample)
EP (1) EP1237537B1 (enExample)
JP (1) JP2003516957A (enExample)
AT (1) ATE336987T1 (enExample)
AU (1) AU2525601A (enExample)
CA (1) CA2394416A1 (enExample)
CY (1) CY1106249T1 (enExample)
DE (1) DE60030319T2 (enExample)
DK (1) DK1237537T3 (enExample)
ES (1) ES2270895T3 (enExample)
FR (1) FR2802097B1 (enExample)
PT (1) PT1237537E (enExample)
WO (1) WO2001043720A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031640A1 (it) 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
AU2004274000B2 (en) * 2003-09-19 2009-07-30 Drugtech Corporation Pharmaceutical delivery system
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
MX2007013631A (es) * 2005-05-09 2008-01-24 Drugtech Corp Composiciones farmaceuticas de liberacion modificada.
EA200870153A1 (ru) * 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
JP2533723B2 (ja) * 1992-12-28 1996-09-11 東興薬品工業株式会社 速乾性ゲルタイプ手指消毒剤
ES2078175B1 (es) * 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
US5902110A (en) * 1995-12-18 1999-05-11 The Block Drug Company Bone regeneration
US5869601A (en) * 1996-04-05 1999-02-09 S. C. Johnson & Son, Inc. Method of stabilizing the viscosity of a thickened composition
WO1998050005A1 (en) * 1997-05-09 1998-11-12 Medlogic Global Corporation Compositions for cosmetic applications
US7064114B2 (en) * 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations

Also Published As

Publication number Publication date
ES2270895T3 (es) 2007-04-16
JP2003516957A (ja) 2003-05-20
FR2802097B1 (fr) 2002-12-13
WO2001043720A1 (fr) 2001-06-21
FR2802097A1 (fr) 2001-06-15
DE60030319D1 (de) 2006-10-05
US20030091642A1 (en) 2003-05-15
CA2394416A1 (fr) 2001-06-21
EP1237537A1 (fr) 2002-09-11
DE60030319T2 (de) 2007-08-30
PT1237537E (pt) 2007-01-31
ATE336987T1 (de) 2006-09-15
AU2525601A (en) 2001-06-25
EP1237537B1 (fr) 2006-08-23
DK1237537T3 (da) 2006-12-27

Similar Documents

Publication Publication Date Title
CY1117370T1 (el) Φαρμακευτικη παστιλια με βραδεια απελευθερωσης του δραστικου παραγοντα
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
DE69828595D1 (de) Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
SE9301489D0 (sv) Veterinary composition
DE69317444D1 (de) Antivirale topische pharmazeutische zusammensetzungen
CY1107711T1 (el) Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων
NO20021013L (no) Vandig geldannet blanding som omfatter en blokk-kopolymer inkluderende minst en vannopplöselig blokk og en hydrofob blokk
CY1108548T1 (el) Βιοπροσκολλητικη γελη βασισμενη σε υδροξυαιθυλοκυτταρινη
ATE336255T1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
UY25544A1 (es) Forma de dosificación de nefazodona
EE04278B1 (et) Pantoprasoolmagneesiumdihüdraat, seda sisaldav ravim ja selle kasutamine
TR200200716T2 (tr) Ketiyapin granülleri
BR9912275A (pt) Formulação de bioimplante
CY1106249T1 (el) Συνθεση υπο τη μορφη πηκτωματος προβλεπομενη ωστε να δεχεται ενα δραστικο παραγοντα σε διαλυση ή εναιωρηση ειδικα για εφαρμογη επι ενος βλεννογονου και μεθοδος παρασκευης
SE9700934D0 (sv) New formulation
DE69716469D1 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
NO942396L (no) Preparat med vedvarende frigiving av anti-endotelin substans
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
CY1107984T1 (el) Aγροχημικος σχηματισμος
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
AR023815A1 (es) Solucion oral de prucalopride
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.